Nuritas applies AI to unlock life-extending bioactive food peptides

Dublin start-up Nuritas which counts Salesforce founder Marc Benioff and U2’s Bono among investors uses data mining of molecules in food to discover fast-track drugs.

Identifying and creating new drugs for diseases may be an expensive and time-consuming challenge but the Dublin start-up company Nuritas may be up to the challenge in a novel way. Founded in 2014 by Dr Nora Khaldi, the company is using artificial intelligence and DNA analysis to discover bioactive peptides that can help prevent and treat diseases within food. The bioactive peptides can be used in a range of products including functional and medical foods, pharmaceuticals and dietary supplements [1].

Longevity.Technology: Nuritas’ way of using food and bioactive peptides to deliver targeted treatments is an innovative approach to developing drugs for various diseases. As many drugs get stuck for years in-between clinical trials and approval, this method could deliver a faster and more efficient way to provide treatment.

The TRL score for this Longevity.Technology domain is currently set at: ‘Technology completes secondary trials and provides further evidence for safety and efficacy.’

TRL7 orange

The TRL score for the technology addressed in this article is: ‘Early proof of concept demonstrated in the laboratory.’

Peptide drug discovery has gained momentum due to peptide therapeutics becoming an efficient way to fill the gap in medical needs. The Nuritas drug discovery platform works quickly and accurately and attempts to deliver a new way of providing treatments beyond traditional drug discovery which is expensive and often fails before it reaches late clinical stages [2].

Nuritas’ approach to alternative drug discovery and development is threefold. The first step is defining the health condition to which they want to target to improve the chances of finding an effective peptide. The second stage consists of using AI to predict the bioactive peptides derived from food sources that could treat or boost resistance to the targeted disease. The final steps include finding a peptide that could work and then unlock it from the food source so that it can be used therapeutically [4].

Nuritas works with many different companies such as BASF (the world’s largest chemical company) and Nestlé, to discover and develop drugs to treat various conditions. Nuritas CEO Emmet Browne said, “In effect, what we do is use artificial intelligence to unlock nature’s secrets. That’s the depth of it.”

Their most recent discovery is a peptide for the prevention of diabetes, it is aimed at maintaining blood sugar levels. The drug compound is in clinical trials to test the drug’s safety and efficacy for treatment. As a recipient of European Horizon 2020 grant from the European Commission, Nuritas is working to use the grant to support the development and commercialisation of the technique.

Nuritas, has raised $65m (£51m) from a number of investors like Salesforce founder Marc Benioff and U2’s Bono. Their machine learning drug discovery process now had a 60% success rate [3].

With collaborations with conglomerates such as Nestlé, the company has the funding and resources to further their research and development making the road to the marketplace a much easier and quicker process. Nuritas and their AI driven process has the potential to be the next big method to not only prevent diseases by more natural and efficient means but also relieve the symptoms and improve the lives of patients suffering a variety of conditions.

[1] https://globalambition.ie/nuritas/
[2] https://www.irishtimes.com/business/health-pharma/dublin-data-mining-health-start-up-nuritas-raises-20m-1.3334027
[3] https://finance.yahoo.com/news/irish-startup-nuritas-expects-to-discover-five-new-drugs-healtcare-ingredients-using-ai-by-2021-050000025.html
[4] https://labiotech.eu/medical/artificial-intelligence-peptides-nuritas/
Image: dominika zarzycka / Shutterstock.com
Salvinija Roznyte
Staff Writer Salvinija Roznyte is a writer and journalist based in London. She graduated in 2018 with a Bachelor's degree majoring in Writing and Journalism with a minor in Film Studies. She is interested in the way modern medical technology changes and shapes our world.

Latest articles

114 year-old cells converted to pluripotent stem cells

AgeX publishes evidence of supercentenarian cellular age reversal: new paper supports hypothesis of no upper age limit for reprogramming cellular aging. This is big...

Placenta blood and personalised Longevity therapies

The placenta is a reservoir of stem cells with minimal ethical concerns. The establishment of placental stem cell biobanks will enable their use in...

Anti-aging drugs in MIT’s 10 Breakthrough Technologies 2020

For the last 20 years MIT Technology Review's Breakthrough Technologies 2020 has been assessing the way we live, work and invest.  Back in 2001, MIT...

Proving the Longevity potential of NAD+

Talking sirtuins, NAD+ and trials with Elysium Health CEO Eric Marcotulli. When it comes to the world of consumer anti-aging supplements, there are few higher-profile...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.